Early diagnosis is critical to reduce the risk of visual impairment in patients with giant cell arteritis. A report on the guidelines for the management of this disease offers practical recommendations; however, further efforts that incorporate collaborative multicenter studies might be needed to reach agreement among clinicians.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gonzalez-Gay, M. A. et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 61, 1454–1461 (2009).
Gonzalez-Gay, M. A. et al. Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 84, 269–276 (2005).
Caselli, R. J. & Hunder, G. G. Neurologic aspects of giant cell (temporal) arteritis. Rheum. Dis. Clin. North. Am. 19, 941–953 (1993).
Dasgupta, B. et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford) doi:10.1093/rheumatology/keq039a.
Salvarani, C. & Hunder, G. G. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurence in a population-based study. Arthritis Rheum. 45, 140–145 (2001).
González-Gay, M. A. et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum. 41, 1497–1504 (1998).
Achkar, A. A., Lie, J. T., Hunder, G. G., O'Fallon, W. M. & Gabriel, S. E. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann. Intern. Med. 120, 987–992 (1994).
Mahr, A. D. et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 56, 2789–2797 (2007).
Martínez-Taboada, V. M. et al. A double-blind placebo controller trial of etanercept in patients with giant cell arteritis and corticosteroids side-effects. Ann. Rheum. Dis. 67, 625–630 (2008).
Salvarani, C. et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford) 48, 250–253 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
González-Gay, M., Rodríguez-Valverde, V. Not losing sight is the issue in GCA management. Nat Rev Rheumatol 6, 440–441 (2010). https://doi.org/10.1038/nrrheum.2010.119
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.119
